Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by longterm56on Oct 04, 2022 12:03pm
127 Views
Post# 35004286

RE:Thursday 10/13

RE:Thursday 10/13Guard your expectations, SPCEO, it can't be all that great of news if they don't consider it "material". -LT
SPCEO1 wrote: If you are letting yourself be sidetracked by the cartoonish trading in the stock related to the IV Push approval, you are missing the main point. In six trading days TH will be giving us some information about TH-1902's performance in the phase 1b trial. We cannot know now exactly what that info will be but since no analyst is currently forecasting anything at all for TH-1902, any positive info should help the share price. And there are plenty of signs the info will be positive on some level. Obviously, there is a chance the info they share will be highly positive andthere is not much of a chance of it being negative given how the  company ahs been actign recently. So, the odds are skewed in a favorable direction for TH shareholders regarding this event. It makes sense for we extremely patient shareholders to wait out these last six days and see what TH tells us about TH-1902 since there is a good chance it may be info that really triggers other investors to finally start paying attention to the stock. Maybe even including another round of crazed retail investors who this time will be dealing with more accurate info!


<< Previous
Bullboard Posts
Next >>